Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)
← catalyst calendarNCT07457918 · readout in 620 d
Sponsored by Verrica Pharmaceuticals Inc. (industry) · VRCA — their whole pipeline →. With Allucent (US) LLC, Myonex LLC, Canfield Scientific Inc., Medidata Solutions and 3 more.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
600estimated
Sites
4
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-03-11 | actual | When the study began enrolling |
| Primary completion | 2028-04-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-05-22 | estimated | The whole study's end, after follow-up |
| First posted | 2026-03-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-05 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Common Warts (Verruca Vulgaris)
- Common Warts
- Human Papilloma Virus (HPV)
- Warts
Intervention
- Combination product: Cantharidin
Primary outcomes
what the primary-completion date above is the date OFIncidence and severity of AEs including LSRs.
measured Day of transition to this LTFU study to End of Study Visit Day 378.
Change from baseline in vital signs (body temperature)
measured Day of transition to this LTFU study to End of Study Visit Day 378.
Change from baseline in vital signs (pulse)
measured Day of transition to this LTFU study to End of Study Visit Day 378.
Concomitant medication use
measured Day of transition to this LTFU study to End of Study Visit Day 378.
Proportion of subjects achieving clearance (reduction to zero) at the Day 378 EOS Visit of all treatable warts present at Baseline*
measured Baseline* to End of Study Visit Day 378.
Permalink · VRCA's whole pipeline · Catalyst calendar · Every registered study · What changed